Obtained the summary report of the Phase I/II clinical study of BDB-001 injection (indication for ANCA-associated vasculitis)
August 2, 2025
Source: drugdu
58
On July 31, Shutaishen announced the recent completion of a Phase I/II clinical study of BDB-001 injection for ANCA-associated vasculitis (AAV). The study confirmed that BDB-001 injection demonstrated significant clinical advantages in achieving steroid reduction, particularly in complete remission rates. Based on the current data, the company will actively advance into a Phase III clinical trial to further validate its clinical benefits in treating AAV patients.
BDB-001 has shown initial success in Phase I/II clinical trials, particularly in terms of hormone reduction and complete remission rates. However, it's important to note that while Shutaishen has been simultaneously developing several innovative drugs in recent years, none of them are yet close to commercialization. This may put pressure on the company's short-term performance. However, given the company's stock price has experienced multiple rounds of speculation in the secondary market, investors should remain cautious.
Source：https://www.phirda.com/artilce_39259.html?module=trackingCodeGenerator
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- After the impact of centralized procurement, this old pharmaceutical company gambled heavily on research and development August 20, 2025
- Zhifei Biological has turned from profit to loss, and the transformation and breakthrough of domestic vaccines have become a trend August 20, 2025
- The subsequent R&D nodes and external licensing expectations of the innovative vaccine pipeline are worth paying attention to August 20, 2025
- Zhifei Bio’s subsidiary’s vaccine application for clinical trial accepted August 20, 2025
- Seven blood metabolites associated with excessive daytime sleepiness August 20, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
